SomapacitanGH BoosterSafety Rating 8/10
Primary research areaAdult growth hormone deficiency
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range1.5-8 mg weekly
AdministrationSubcutaneous injection
Safety8/10 · FDA-approved (Sogroya)
NCAA D1Banned
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Somapacitan
Mechanism of action
Long-acting recombinant GH with albumin-binding fatty acid
Safety profile
Peripheral edema, arthralgia, glucose intolerance · Approved adult GH deficiency; weekly injection; well-characterized; similar safety to daily GH
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Somapacitan below your target.
Related pages